AF patients who underwent catheter ablation while being treated with uninterrupted Pradaxa® experienced less major bleeding and fewer serious adverse events compared to those treated with uninterrupted warfarin.
The results were presented in a late-breaking session at the American College of Cardiology 66th Annual Scientific Session in Washington and simultaneously published in the New England Journal of Medicine.1,2 In the RE-CIRCUIT® trial, uninterrupted Pradaxa® significantly reduced the risk of major bleeding complications compared with uninterrupted warfarin: The trial showed a 5.3% absolute risk reduction in its primary endpoint, with major bleeds occurring in 5/317 of patients receiving Pradaxa® versus 22/318 of patients receiving warfarin (77.2% relative risk reduction).
635 patients with paroxysmal or persistent AF undergoing catheter ablation were included in the RE-CIRCUIT® trial.
These patients were reflective of the types of patients undergoing the procedure in routine clinical practice, providing relevant new data to treating physicians.1,2 “These results are exciting news for the medical community,” said Professor Hugh Calkins, Chairman of the RE-CIRCUIT® Study Steering Committee and Professor of Cardiology and Director of the Electrophysiology Laboratory and Arrhythmia Service, Johns Hopkins Hospital, Baltimore, USA.
Boehringer Ingelheim launched Pradaxa®, the first NOAC for stroke risk reduction in patients with AF12,13, and in 2015 gained approval for idarucizumab (Praxbind®), the first specific NOAC reversal agent for use in emergency situations to reverse the anticoagulant effect of dabigatran.14,15 Idarucizumab is widely available and stocked in over 7,500 hospitals worldwide, including in the United States, the European Union and Japan.16 https://www.boehringer-ingelheim.com/press-release/ACC17-RE-CIRCUIT FOR MEDIA ONLY: Exclusive content on RE-CIRCUIT study now available.